Name: FG2216
Price: 276.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    FG-2216 is a potent HIF-prolyl hydroxylase inhibitor. IC50 = 3.9 μM for PDH2 enzyme.
    HIFs (hypoxia inducible factors) are transcription factor that activated by low oxygen availability. It leads to cellular, tissue and organismal adaptive response to hypoxia. Increased hemoglobin
    levels are associated with intrauterine hypoxia. In cooperation with other transcriptional coactivators, HIF induces transcription of genes that ameliorate the effects of hypoxia, including erythropoietin and its receptor.
    In rhesus macaques, FG-2216 reversibly activates endogenous erythropoietin (82- to 309-fold at 60 mg/kg), and as early as 4 hours after oral administration of FG-2216, circulating plasma Epo levels increases. [1]
    Chronic administration of FG-2216 is well tolerated and induces erythropoiesis in rhesus macaques. It also induced a small elevation of hemoglobin expression in vivo. FG-2216–treated animals exerts rise in the percentage of hemoglobin-containing reticulocytes (% F+ retics) 1 to 2 weeks after chronic dosing began. [1]
- Properties
  - Alternative Name
    
    (Z)-2-(((1-chloro-4-hydroxyisoquinolin-3-yl)(hydroxy)methylene)amino)acetic acid
    
    CAS Number
    
    223387-75-5
    
    Molecular Formula
    
    C12H9ClN2O4
    
    Molecular Weight
    
    280.66
    
    Appearance
    
    A solid
    
    Purity
    
    98.55%
    
    Solubility
    
    insoluble in H2O; ≥14.05 mg/mL in DMSO; ≥5.12 mg/mL in EtOH with ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

FG2216

FG2216

Background

We Also Recommend

MHY1485

Mutant IDH1-IN-1

Pexidartinib (PLX3397)